LCAT deficiency promotes hepatocellular carcinoma progression and lenvatinib resistance by promoting triglyceride catabolism and fatty acid oxidation
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217469 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Min Xu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and C…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Quinolines, Phenylurea Compounds. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 79 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, PR China.
- Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, PR China; Dep…
- Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer of Shanghai Municipal Health Commission, Shanghai, 201199, PR China; Institute of Fudan-Minhang Academic Health System, Minhang Hosp…
- Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
- Central Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, PR China. Electronic address: xiaoni-kong@126.com.
- Graduate Institute of Biomedical Sciences, Institute of Biochemistry and Molecular Biology, Research Center for Cancer Biology, Cancer Biology and Precision Therapeutics Center, and Center for Molecular Medicine, China…
Zitieren
APA
Xu, M., Xie, P., Liu, S., Gao, X., Yang, S., Hu, Z., Zhao, Y., Yi, Y., Dong, Q., Bruns, C., Kong, X., Hung, M. C., Ren, N., & Zhou, C. (2025). LCAT deficiency promotes hepatocellular carcinoma progression and lenvatinib resistance by promoting triglyceride catabolism and fatty acid oxidation. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217469
Vancouver
Xu M, Xie P, Liu S, Gao X, Yang S, Hu Z, et al. LCAT deficiency promotes hepatocellular carcinoma progression and lenvatinib resistance by promoting triglyceride catabolism and fatty acid oxidation. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217469
BibTeX
@article{Xu2025,
author = {Xu, Min and Xie, Peiyi and Liu, Shaoqing and Gao, Xukang and Yang, Shiguang and Hu, Zhiqiu and Zhao, Yue and Yi, Yong and Dong, Qiongzhu and Bruns, Christiane and Kong, Xiaoni and Hung, Mien-Chie and Ren, Ning and Zhou, Chenhao},
title = {LCAT deficiency promotes hepatocellular carcinoma progression and lenvatinib resistance by promoting triglyceride catabolism and fatty acid oxidation},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217469}
}
EUVIMED